Clinical trials · Illinois
Prostate Cancer (Adenocarcinoma) clinical trials in Illinois
We’re tracking 54 recruiting prostate cancer (adenocarcinoma) studies with a site in Illinois — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Illinois
- NCT06215508Recruiting
Smartwatch and geriatric assessment for older men with prostate cancer
This trial tests whether using a smartwatch along with a geriatric assessment can help doctors better manage the health of older men with metastatic prostate cancer who are about to start a new type of hormone therapy. It aims to improve quality of life and treatment outcomes.
Chicago, IllinoisAges 18 minutes+ - NCT06616155RecruitingPhase 1/Phase 2
Ruxolitinib and Enzalutamide for Resistant Prostate Cancer
This trial tests two drugs—ruxolitinib and enzalutamide—together to see if they can help men whose prostate cancer has spread and stopped responding to abiraterone. It is for those whose cancer grew quickly on abiraterone.
Chicago, IllinoisAges 18 years+ - NCT06636682RecruitingPhase 2
Vaccine for men with high-risk prostate cancer after surgery
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
Chicago, IllinoisAges Any age - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Chicago, IllinoisAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT05852041RecruitingEarly Phase 1
PET-MRI scan to find prostate cancer before active surveillance
This early-phase study tests a special PET-MRI scan using rhPSMA-73 to better detect prostate cancer areas in men who would otherwise choose active surveillance. It may help doctors see where (and how much) cancer is present before deciding on treatment.
Chicago, IllinoisAges 18 years+ - NCT01492972RecruitingPhase 3
Lighter radiation, with or without hormone suppression
This Phase 3 trial tests whether giving a smaller amount of radiation (“hypo-fractionated” means fewer, larger sessions) can work as well as standard approaches for intermediate-risk prostate cancer. It also compares adding hormone therapy (“androgen suppression”) to radiation versus using radiation alone.
Warrenville, IllinoisAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Alton, IllinoisAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Chicago, IllinoisAges 18 years+ - NCT06136650RecruitingPhase 3
Study of a new drug for advanced prostate cancer
This study tests a new oral drug called opevesostat against another standard hormone therapy for men with advanced prostate cancer that has spread and is no longer controlled by a first hormone therapy. It's for men who have not had chemotherapy for this stage and who have not used a PARP inhibitor or chose not to.
Elmhurst, IllinoisAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Chicago, IllinoisAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Chicago, IllinoisAges 18 years+ - NCT06629779RecruitingPhase 3
Study of Mevrometostat for Advanced Prostate Cancer
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Lisle, IllinoisAges 18 years+ - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
Lisle, IllinoisAges 18 years+ - NCT06764485RecruitingPhase 3
Comparing a new drug to standard therapy for advanced prostate cancer
This trial tests a new medicine (BMS-986365) against the doctor's choice of standard therapy for men with metastatic castration-resistant prostate cancer. It aims to see which treatment works better and is safer.
Chicago, IllinoisAges 18 years+ - NCT06879041RecruitingPhase 1
Study of a radiation drug for advanced prostate cancer
This trial tests a new drug that delivers radiation directly to cancer cells. It is for men with metastatic castration-resistant prostate cancer that has progressed after other treatments.
Chicago, IllinoisAges 18 years+ - NCT06022822RecruitingPhase 2
Urolithin A supplement before prostate cancer surgery
This trial tests whether taking a supplement called urolithin A for a few weeks before prostate removal surgery can help. The supplement comes from pomegranates and may slow cancer growth. You may qualify if you have prostate cancer, are planning surgery within 3-6 weeks, and have not had prior treatment like hormone therapy.
Chicago, IllinoisAges 18 years+ - NCT07611110RecruitingPhase 3
AZD2265 vs standard care for advanced prostate cancer
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
O'Fallon, IllinoisAges 18 years+ - NCT05593497RecruitingPhase 2
Combination therapy before prostate surgery for high-risk prostate cancer
This study tests a combination of hormone therapy and a targeted drug before prostate surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach can improve outcomes.
Chicago, IllinoisAges 18 years+ - NCT07594106RecruitingPhase 1/Phase 2
New immunotherapy for advanced prostate or kidney cancer
This trial tests new experimental drugs (REGN15505 and REGN4336) designed to target and attack cancer cells in advanced prostate cancer or kidney cancer. These drugs work by boosting your immune system to recognize and destroy cancer, and may be combined with other approved immunotherapy drugs.
Zion, IllinoisAges 18 years+ - NCT06235697RecruitingPhase 3
Hormone therapy with or without lymph node radiation for prostate cancer
This trial tests combining hormone therapy with different types of radiation (including high-dose external beam and brachytherapy) for men with prostate cancer that has a higher chance of coming back. It aims to see if adding radiation to the lymph nodes helps control the cancer better.
Shiloh, IllinoisAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Lisle, IllinoisAges 18 years+ - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Hinsdale, IllinoisAges 18 years+ - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Chicago, IllinoisAges 18 years+
Prostate Cancer (Adenocarcinoma) trials by city in Illinois
Where these studies are running in Illinois
Institutions with a site for the recruiting prostate cancer (adenocarcinoma) studies listed above.
- University of Chicago · 7 studies
- Duly Health and Care · 3 studies
- Northwestern University · 3 studies
- Research Site · 3 studies
- University of Illinois · 3 studies
- Illinois CancerCare-Peoria · 2 studies
- Memorial Hospital East · 2 studies
- Accellacare of Duly
What taking part in a prostate cancer (adenocarcinoma) study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Prostate Cancer (Adenocarcinoma) trials in other states
Common questions
- Are there prostate cancer (adenocarcinoma) clinical trials in Illinois?
- Yes. We're currently tracking 54 recruiting prostate cancer (adenocarcinoma) studies with a site in Illinois, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a prostate cancer (adenocarcinoma) study in Illinois?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Illinois to take part?
- Not necessarily. These studies have a site in Illinois, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New prostate cancer (adenocarcinoma) studies open in Illinois regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.